Denise R Nebgen1, Karen H Lu2, Sue Rimes2, Elizabeth Keeler2, Russell Broaddus3, Mark F Munsell4, Patrick M Lynch5. 1. Department of Gynecologic Oncology and Reproductive Medicine, The University Of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: dnebgen@mdanderson.org. 2. Department of Gynecologic Oncology and Reproductive Medicine, The University Of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 3. Department of Pathology, The University Of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 4. Department of Biostatistics, The University Of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. 5. Department of Gastroenterology, Hepatology, and Nutrition, The University Of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Abstract
OBJECTIVE: Endometrial biopsy (EMBx) and colonoscopy performed under the same sedation is termed combined screening and has been shown to be feasible and to provide a less painful and more satisfactory experience for women with Lynch syndrome (LS). However, clinical results of these screening efforts have not been reported. The purpose of this study was to evaluate the long-term clinical outcomes and patient compliance with serial screenings over the last 10.5 years. METHODS: We retrospectively analyzed the data for 55 women with LS who underwent combined screening every 1-2 years between 2002 and 2013. Colonoscopy and endometrial biopsy were performed by a gastroenterologist and a gynecologist, with the patient under conscious sedation. RESULTS: Out of 111 screening visits in these 55 patients, endometrial biopsies detected one simple hyperplasia, three complex hyperplasia, and one endometrioid adenocarcinoma (FIGO Stage 1A). Seventy-one colorectal polyps were removed in 29 patients, of which 29 were tubular adenomas. EMBx in our study detected endometrial cancer in 0.9% (1/111) of surveillance visits, and premalignant hyperplasia in 3.6% (4/111) of screening visits. No interval endometrial or colorectal cancers were detected. CONCLUSIONS: Combined screening under sedation is feasible and less painful than EMBx alone. Our endometrial pathology detection rates were comparable to yearly screening studies. Our results indicate that screening of asymptomatic LS women with EMBx every 1-2 years, rather than annually, is effective in the early detection of (pre)cancerous lesions, leading to their prompt definitive management, and potential reduction in endometrial cancer.
OBJECTIVE: Endometrial biopsy (EMBx) and colonoscopy performed under the same sedation is termed combined screening and has been shown to be feasible and to provide a less painful and more satisfactory experience for women with Lynch syndrome (LS). However, clinical results of these screening efforts have not been reported. The purpose of this study was to evaluate the long-term clinical outcomes and patient compliance with serial screenings over the last 10.5 years. METHODS: We retrospectively analyzed the data for 55 women with LS who underwent combined screening every 1-2 years between 2002 and 2013. Colonoscopy and endometrial biopsy were performed by a gastroenterologist and a gynecologist, with the patient under conscious sedation. RESULTS: Out of 111 screening visits in these 55 patients, endometrial biopsies detected one simple hyperplasia, three complex hyperplasia, and one endometrioid adenocarcinoma (FIGO Stage 1A). Seventy-one colorectal polyps were removed in 29 patients, of which 29 were tubular adenomas. EMBx in our study detected endometrial cancer in 0.9% (1/111) of surveillance visits, and premalignant hyperplasia in 3.6% (4/111) of screening visits. No interval endometrial or colorectal cancers were detected. CONCLUSIONS: Combined screening under sedation is feasible and less painful than EMBx alone. Our endometrial pathology detection rates were comparable to yearly screening studies. Our results indicate that screening of asymptomatic LS women with EMBx every 1-2 years, rather than annually, is effective in the early detection of (pre)cancerous lesions, leading to their prompt definitive management, and potential reduction in endometrial cancer.
Authors: Wouter H de Vos tot Nederveen Cappel; Fokko M Nagengast; Gerrit Griffioen; Fred H Menko; Babs G Taal; Jan H Kleibeuker; Hans F Vasen Journal: Dis Colon Rectum Date: 2002-12 Impact factor: 4.585
Authors: Randall W Burt; Jamie A Cannon; Donald S David; Dayna S Early; James M Ford; Francis M Giardiello; Amy L Halverson; Stanley R Hamilton; Heather Hampel; Mohammad K Ismail; Kory Jasperson; Jason B Klapman; Audrey J Lazenby; Patrick M Lynch; Robert J Mayer; Reid M Ness; Dawn Provenzale; M Sambasiva Rao; Moshe Shike; Gideon Steinbach; Jonathan P Terdiman; David Weinberg; Mary Dwyer; Deborah Freedman-Cass Journal: J Natl Compr Canc Netw Date: 2013-12-01 Impact factor: 11.908
Authors: Kathleen M Schmeler; Henry T Lynch; Lee-may Chen; Mark F Munsell; Pamela T Soliman; Mary Beth Clark; Molly S Daniels; Kristin G White; Stephanie G Boyd-Rogers; Peggy G Conrad; Kathleen Y Yang; Mary M Rubin; Charlotte C Sun; Brian M Slomovitz; David M Gershenson; Karen H Lu Journal: N Engl J Med Date: 2006-01-19 Impact factor: 91.245
Authors: Isis Dove-Edwin; Dominique Boks; Sheila Goff; Gemma G Kenter; Robert Carpenter; Hans F A Vasen; Huw J W Thomas Journal: Cancer Date: 2002-03-15 Impact factor: 6.860
Authors: Laura Renkonen-Sinisalo; Ralf Bützow; Arto Leminen; Pentti Lehtovirta; Jukka-Pekka Mecklin; Heikki J Järvinen Journal: Int J Cancer Date: 2007-02-15 Impact factor: 7.396
Authors: Elena Stoffel; Bhramar Mukherjee; Victoria M Raymond; Nabihah Tayob; Fay Kastrinos; Jennifer Sparr; Fei Wang; Prathap Bandipalliam; Sapna Syngal; Stephen B Gruber Journal: Gastroenterology Date: 2009-07-18 Impact factor: 22.682
Authors: Jan J Koornstra; Marian Je Mourits; Rolf H Sijmons; Annemarie M Leliveld; Harry Hollema; Jan H Kleibeuker Journal: Lancet Oncol Date: 2009-04 Impact factor: 41.316
Authors: Taina T Nieminen; Annette Gylling; Wael M Abdel-Rahman; Kyösti Nuorva; Markku Aarnio; Laura Renkonen-Sinisalo; Heikki J Järvinen; Jukka-Pekka Mecklin; Ralf Bützow; Päivi Peltomäki Journal: Clin Cancer Res Date: 2009-09-01 Impact factor: 12.531
Authors: Kathleen F Mittendorf; Sarah Knerr; Tia L Kauffman; Nangel M Lindberg; Katherine P Anderson; Heather Spencer Feigelson; Marian J Gilmore; Jessica Ezzell Hunter; Galen Joseph; Stephanie A Kraft; Jamilyn M Zepp; Sapna Syngal; Benjamin S Wilfond; Katrina A B Goddard Journal: JCO Precis Oncol Date: 2021-11-03
Authors: Jorien Helder-Woolderink; Geertruida de Bock; Harry Hollema; Magda van Oven; Marian Mourits Journal: Fam Cancer Date: 2017-04 Impact factor: 2.375